REAL TIME REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION OF URINARY CYTOKERATIN 20 DETECTS TRANSITIONAL CELL CARCINOMA CELLS
2001; Lippincott Williams & Wilkins; Volume: 166; Issue: 6 Linguagem: Inglês
10.1016/s0022-5347(05)65521-8
ISSN1527-3792
AutoresTakahiro Inoue, Hayao Nakanishi, Ken-ichi Inada, T Hioki, Masae Tatematsu, Yoshiki Sugimura,
Tópico(s)Nuclear Structure and Function
ResumoNo AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Dec 2001REAL TIME REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION OF URINARY CYTOKERATIN 20 DETECTS TRANSITIONAL CELL CARCINOMA CELLS TAKAHIRO INOUE, HAYAO NAKANISHI, KEN-ICHI INADA, TAKUICHI HIOKI, MASAE TATEMATSU, and YOSHIKI SUGIMURA TAKAHIRO INOUETAKAHIRO INOUE , HAYAO NAKANISHIHAYAO NAKANISHI , KEN-ICHI INADAKEN-ICHI INADA , TAKUICHI HIOKITAKUICHI HIOKI , MASAE TATEMATSUMASAE TATEMATSU , and YOSHIKI SUGIMURAYOSHIKI SUGIMURA View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)65521-8AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We evaluate the diagnostic use of cytokeratin 20 messenger (m) RNA quantitation in urine as a marker of urothelial transitional cell carcinoma using the real time reverse transcriptase polymerase chain reaction (RT-PCR). Materials and Methods: Spontaneously voided urine was obtained from 47 patients with urothelial transitional cell carcinoma (carcinoma group), 19 other urological diseases (noncarcinoma group) and 27 healthy volunteers (control group). Quantification of cytokeratin 20 was performed with mRNA extracted from urine samples with primers and hybridization probes specific for cytokeratin 20 on a LightCycler instrument (Roche Diagnostics Corp., Indianapolis, Indiana). Results: This method allowed reproducible quantitation of 10 to 106 cytokeratin 20 expressing colon carcinoma cells per 107 peripheral blood leukocytes, comparable to the sensitivity of conventional RT-PCR with a wide linear measuring range. Cytokeratin 20 mRNA values in the carcinoma group (mean 35,850) were significantly higher than noncarcinoma (171) and control groups (4.55, p <0.0001 and <0.0001, respectively). Urinary cytokeratin 20 mRNA values significantly correlated with tumor grade, urinary cytological class, immunostaining pattern and depth of tumor invasion. Sensitivity and specificity of real time RT-PCR with a cutoff value of 15 were 81% and 83%, whereas those of conventional cytology were 28% and 100%, respectively. Conclusions: These results indicate that real time cytokeratin 20 RT-PCR is a sensitive, quantitative, rapid and specific method to detect free cancer cells in the urine, with good potential for monitoring recurrence of urothelial transitional cell carcinoma. References 1 : Urothelial tumors of the urinary tract. In: . Philadelphia: W. B. Saunders Co.1998: 2327. chapt. 77. Google Scholar 2 : Initial evaluation of the bladder tumor antigen test in superficial bladder cancer. J Urol1996; 155: 475. Link, Google Scholar 3 : Multicenter trial of the quantitative BTA TRAK assay in the detection of bladder cancer. Clin Chem1999; 45: 427. Google Scholar 4 : Improved detection of recurrent bladder cancer using the Bard BTA stat test. Urology1997; 50: 349. Google Scholar 5 : A multicenter trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer. J Urol1997; 158: 801. Link, Google Scholar 6 : Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol1996; 156: 363. Link, Google Scholar 7 : NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer. J Urol1999; 161: 62. Link, Google Scholar 8 : Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies. Am J Pathol1992; 140: 427. Google Scholar 9 : Expression of cytokeratin 20 in urinary cytology of patients with bladder carcinoma. Cancer1998; 82: 349. Google Scholar 10 : Cytokeratin 20: a new marker for early detection of bladder cell carcinoma. J Urol1998; 160: 1971. Link, Google Scholar 11 : Cytokeratin 20 as an objective marker of urothelial dysplasia. Br J Urol1996; 78: 870. Google Scholar 12 : Re: Cytokeratin 20: a new marker for early detection of bladder cell carcinoma (letter to the editor). J Urol1999; 162: 501. Abstract, Google Scholar 13 : Detection of specific polymerase chain reaction product by utilizing the 5′→3′ exonuclease activity of Thermus aquaticus DNA polymerase. Proc Natl Acad Sci USA1991; 88: 7276. Google Scholar 14 : Continuous fluorescence monitoring of rapid cycle DNA amplification. Biotechniques1997; 22: 130. Google Scholar 15 : TheLightCyclerTM: a microvolume multisample fluorimeter with rapid temperature control. Biotechniques1997; 22: 176. Google Scholar 16 : Improved quantitation of minimal residual disease in multiple myeloma using realtime polymerase chain reaction and plasmid-DNA complementarity determining region III standards. Cancer Res1998; 58: 3957. Google Scholar 17 : LightCycler technology for the quantitation of bcr/abl fusion transcripts. Cancer Res1999; 59: 3171. Google Scholar 18 : Rapid genotyping of hemochromatosis gene mutations on the LightCycler with fluorescent hybridization probes. Clin Chem1999; 45: 1875. Google Scholar 19 : Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for realtime quantitative RT-PCR. Leukemia1999; 13: 1825. Google Scholar 20 : Real-time t(11;14) and t(14;18) PCR assays provide sensitive and quantitative assessments of minimal residual disease (MRD). Leukemia1999; 13: 1833. Google Scholar 21 : Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes. Leukemia1998; 12: 2006. Google Scholar 22 : Molecular diagnostic detection of free cancer cells in the peritoneal cavity of patients with gastrointestinal and gynecologic malignancies. Cancer Chemother Pharmacol, suppl.1999; 43: S32. Google Scholar 23 : Rapid quantitative detection of carcinoembryonic antigen-expressing free tumor cells in the peritoneal cavity of gastric-cancer patients with realtime RT-PCR on the LightCycler. Int J Cancer2000; 89: 411. Google Scholar 24 : Quantification of micrometastasis in lymph nodes of colorectal cancer using real-time fluorescence polymerase chain reaction. Int J Oncol2000; 16: 289. Google Scholar 25 : Prognostic significance of occult bone marrow micrometastases of breast cancer detected by quantitative polymerase chain reaction for cytokeratin 19 mRNA. Jpn J Cancer Res2000; 91: 918. Google Scholar 26 : Detection of MUC-1 expressing mammary carcinoma cells in the peripheral blood of breast cancer patients by realtime polymerase chain reaction. Clin Cancer Res2000; 6: 3117. Google Scholar 27 : Quantitative measurement of telomerase reverse transcriptase (hTERT) mRNA in urothelial cell carcinomas. Int J Cancer2000; 87: 217. Google Scholar 28 : Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem1987; 162: 156. Google Scholar 29 : Enhanced expression of a glyceraldehyde-3-phosphate dehydrogenase gene in human lung cancers. Cancer Res1987; 47: 5616. Google Scholar 30 : Expression of cytokeratin 20 redefines urothelial papillomas of the bladder. Lancet1999; 353: 974. Google Scholar 31 : Cytokeratin 20 expression by non-invasive transitional cell carcinomas: potential for distinguishing recurrent from non-recurrent disease. Histopathology1995; 27: 169. Google Scholar 32 : CK 20 gene expression: technical limits for the detection of circulating tumor cells. Anticancer Res1999; 19: 2073. Google Scholar 33 : The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology1982; 143: 29. Google Scholar 34 : A method of comparing the areas under receiver operating characteristics curves derived from the same cases. Radiology1983; 148: 839. Google Scholar 35 : False-negative peritoneal cytology in metastatic ovarian carcinoma. Obstet Gynecol1986; 68: 619. Google Scholar From the Department of Urology, Aichi Cancer Center Hospital and Laboratory of Pathology, Aichi Cancer Center Research Institute, Nagoya, Japan© 2001 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited ByOKEGAWA T, KINJO M, NUTAHARA K and HIGASHIHARA E (2018) VALUE OF REVERSE TRANSCRIPTION POLYMERASE CHAIN ASSAY IN PERIPHERAL BLOOD OF PATIENTS WITH UROTHELIAL CANCERJournal of Urology, VOL. 171, NO. 4, (1461-1466), Online publication date: 1-Apr-2004.SCHRADER A, LAUBER J, LECHNER O, HEIDENREICH A, HOFMANN R and BUER J (2018) Application of Real-Time Reverse Transcriptase-Polymerase Chain Reaction in Urological OncologyJournal of Urology, VOL. 169, NO. 5, (1858-1864), Online publication date: 1-May-2003. Volume 166Issue 6December 2001Page: 2134-2141 Advertisement Copyright & Permissions© 2001 by American Urological Association, Inc.Keywordscarcinoma, transitional cellkeratinurinereverse transcriptase polymerase chain reactioncytologyMetricsAuthor Information TAKAHIRO INOUE More articles by this author HAYAO NAKANISHI More articles by this author KEN-ICHI INADA More articles by this author TAKUICHI HIOKI More articles by this author MASAE TATEMATSU More articles by this author YOSHIKI SUGIMURA More articles by this author Expand All Advertisement PDF DownloadLoading ...
Referência(s)